These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20080285)

  • 1. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent.
    Nakatomi Y; Nakashima T; Gokudan S; Miyazaki H; Tsuji M; Hanada-Dateki T; Araki T; Tomokiyo K; Hamamoto T; Ogata Y
    Thromb Res; 2010 May; 125(5):457-63. PubMed ID: 20080285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
    Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
    Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, distribution, and excretion of 125I-labeled human plasma-derived-FVIIa and -FX with MC710 (FVIIa/FX mixture) in rats.
    Nakatomi Y; Tsuji M; Nakashima T; Gokudan S; Miyazaki H; Tomokiyo K; Ogata Y; Harano S; Matsui H; Shigaki T; Nakamura T; Mogi M
    Thromb Res; 2012 Jan; 129(1):62-7. PubMed ID: 21621824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma-derived factors VIIa and X mixtures (Byclot
    Ochi S; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2020 Jun; 111(6):779-785. PubMed ID: 32030609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
    Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of factor VIII--bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors: thrombin generation test in the presence of collagen-activated platelets.
    Sultan Y; Loyer F
    J Lab Clin Med; 1993 Mar; 121(3):444-52. PubMed ID: 8445292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.
    Shirayama R; Takedani H; Chikasawa Y; Ishiguro A; Ishimura M; Isobe K; Uchiba M; Ogata Y; Kakuda H; Kusuhara K; Shirahata A
    Blood Coagul Fibrinolysis; 2019 Dec; 30(8):385-392. PubMed ID: 31738288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic modeling sheds light on the mode of action of recombinant factor VIIa on thrombin generation.
    Mitrophanov AY; Reifman J
    Thromb Res; 2011 Oct; 128(4):381-90. PubMed ID: 21641634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
    Gray LD; Hussey MA; Larson BM; Machlus KR; Campbell RA; Koch G; Ezban M; Hedner U; Wolberg AS
    Thromb Res; 2011 Dec; 128(6):570-6. PubMed ID: 21561645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
    Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
    Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A possible mechanism of action of activated factor VII independent of tissue factor.
    Monroe DM; Hoffman M; Oliver JA; Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S15-20. PubMed ID: 9819024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
    Hoffman M; Monroe DM; Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S61-5. PubMed ID: 9819030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trial.
    Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2012 Jan; 18(1):94-101. PubMed ID: 21535327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
    Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
    J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrin gel structure obtained with a FVIIa analogue with enhanced FX-activating potential in haemophilia.
    He S; Ezban M; Bark N; Persson E; Hedner U
    Thromb Haemost; 2009 Oct; 102(4):790-2. PubMed ID: 19806268
    [No Abstract]   [Full Text] [Related]  

  • 20. Protein disulfide isomerase has no stimulatory chaperone effect on factor X activation by factor VIIa-soluble tissue factor.
    Persson E
    Thromb Res; 2008; 123(1):171-6. PubMed ID: 18550154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.